Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Colorectal Cancer Metastatic 3Advanced Solid Tumors 3Neoplasm Metastasis 2Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Metastatic Gastric Adenocarcinoma 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Endometrial Neoplasms 1ESCC 1Desmoid Tumors 1Craniopharyngioma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anal Cancer Metastatic 1Advanced/Metastatic Solid Tumors 1Adenomatous Polyposis Coli 1

Interventions

Gemcitabine 97130-nm albumin-bound paclitaxel 47Albumin-Bound Paclitaxel 36Oxaliplatin 27Fluorouracil 26Capecitabine 20Taxes 19Leucovorin 19pembrolizumab 18Cyclophosphamide 18Irinotecan 16Bevacizumab 12fludarabine 11Nivolumab 11Cetuximab 11Cisplatin 10durvalumab 8Radiotherapy 8spartalizumab 7aldesleukin 7Erlotinib Hydrochloride 7Drug Therapy 7avelumab 6Radiosurgery 6Paclitaxel 6irinotecan sucrosofate 5folfirinox 5Ipilimumab 5Injections 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Emory University

Phase 1/2 Active not recruiting
64 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡